Social Capital Suvretta I (NASDAQ:DNAA) announced in an 8-K this afternoon that its shareholders have approved its combination with digital medicine company Akili Interactive at a special meeting held yesterday.
Approximately 99.09% of DNAA shareholders opted to redeem their shares, leaving just 227,252 shares left in the SPAC’s trust. This marks the 4th highest redemption amount throughout 2022 thus far trailing behind Agrico, CC Neuberger Principal Holdings II, and ITHAX, which saw redemptions of 99.8%, 99.4% and 99.4%, respectively.
Akili was able to raise more than $163 million from the transaction, before deducting transaction expenses and advisory fees, which, together with cash on hand, the company expects will be sufficient to fund at least 24 months of business operations. Proceeds from the deal will be used to fund the commercial launch of EndeavorRx, a prescription digital therapeutic for pediatric ADHD, as well as its expansion into further patient populations.
Social Capital Suvretta I backed the deal with a $162 million PIPE at $10 per share. Social Capital put up $100 million of the PIPE with the remaining $62 million split among Suvretta Capital’s Averill strategy, Apeiron Investment Group, Temasek, PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners, and Omidyar Technology Ventures.
The newly formed company, Akili, Inc., is now expected to start trading on The Nasdaq under the new ticker symbol “AKLI” on August 22, 2022.
The SPAC announced the $1 billion deal with Akili earlier this year on January 26, 2022. Boston-based Akili is developing a range of video games designed to serve as digital therapeutics for patients suffering from ADHD, autism, multiple sclerosis and other cognitive ailments.
- Morgan Stanley & Co. LLC and Cowen and Company, LLC are serving as financial advisors to Akili.
- Morgan Stanley, Credit Suisse, and Cowen are serving as co-placement agents to SCS with respect to the portion of the PIPE financing raised from non-insider qualified institutional buyers and institutional accredited investors.
- Morgan Stanley, Credit Suisse, and Cowen are not acting as agents or participating in any role with respect to, and will not earn any fees from, the portion of the PIPE financing raised from insiders and individual investors.
- Credit Suisse and Cowen are serving as capital markets advisors to Akili.
- BofA Securities, Inc. is acting as capital markets advisor to SCS.
- Goodwin Procter LLP is serving as legal counsel to Akili.
- Wachtell, Lipton, Rosen & Katz is serving as legal counsel to SCS.
- Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to the PIPE placement agents.
Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...